Vanda’s VCA-894A Receives FDA Rare Pediatric Disease Designation for Ultra-Rare CMT2S

Vanda Pharmaceuticals has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for VCA-894A, its investigational antisense oligonucleotide (ASO) therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). The designation was granted by the FDA’s Office of Orphan Products Development and Office of Pediatric Therapeutics, recognizing the serious pediatric burden of this exceptionally rare inherited neurological disorder.

The regulatory milestone strengthens the development pathway for VCA-894A, an individualized genetic therapy created for a patient diagnosed in early childhood with a unique genetic form of CMT2S. According to Vanda, the specific disease-causing variant targeted by the therapy has not been identified in any other known patient.

Personalized Antisense Therapy Targets an Ultra-Rare Genetic Mutation

VCA-894A is an antisense oligonucleotide therapy that targets a disease-causing genetic mutation responsible for a rare subtype of Charcot-Marie-Tooth disease. Antisense therapies work by binding to RNA molecules to alter gene expression or reduce production of harmful proteins, offering a precision medicine approach for inherited disorders caused by specific genetic variants.

CMT2S is an inherited axonal neuropathy characterized by progressive degeneration of peripheral nerves, resulting in worsening muscle weakness, sensory loss, impaired motor function, and, in severe cases, loss of independent ambulation. The condition affects fewer than one in one million people worldwide, making it among the rarest forms of Charcot-Marie-Tooth disease. Clinical severity varies depending on the underlying genetic mutation, highlighting the need for mutation-specific therapeutic approaches.

The FDA concluded that CMT2S meets the statutory definition of a rare pediatric disease because it is a serious, life-threatening condition whose manifestations primarily occur from birth through 18 years of age.

Development Program Advances Despite Highly Individualized Patient Population

Because VCA-894A was developed for a single patient carrying a previously unreported genetic variant, Vanda has not disclosed a conventional clinical development program involving large patient cohorts or trial efficacy data. Instead, the program represents an individualized precision medicine strategy for treating an ultra-rare neurogenetic disorder where standard drug development is often not feasible.

The company stated that it will continue working closely with the FDA as development progresses.

FDA Designation Highlights Significant Unmet Need

Commenting on the designation, Mihael H. Polymeropoulos, MD, President, Chief Executive Officer and Chairman of Vanda Pharmaceuticals, said CMT2S is a devastating inherited neuropathy with limited treatment options for affected patients and families. He noted that the FDA’s recognition underscores the substantial unmet medical need in this pediatric population while supporting continued development of a potentially transformative therapeutic option.

Rare Pediatric Disease Status May Offer Regulatory Incentives

The Rare Pediatric Disease Designation is intended to encourage development of therapies for serious or life-threatening rare diseases that predominantly affect children. If VCA-894A ultimately satisfies all statutory requirements and receives FDA approval, Vanda could become eligible for a Rare Pediatric Disease Priority Review Voucher, which can be used for expedited FDA review of another marketing application or transferred to another company.

While the designation does not guarantee approval, it provides important regulatory support as Vanda advances one of the few individualized antisense programs targeting an ultra-rare form of Charcot-Marie-Tooth disease. Continued regulatory engagement will determine the next steps toward potential clinical development and future marketing authorization.

Reference

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S